Source: Davit Kirakosyan
Evercore ISI Downgrades Health Catalyst
Evercore ISI recently downgraded Health Catalyst (NASDAQ:HCAT) from an Outperform to In Line rating, and reduced its price target from $6.00 to $4.00. This decision comes as a result of growing uncertainties surrounding the firm’s short- and long-term financial outlook, leading to a roughly 4% intra-day drop in the company’s shares.
Downside Risks Remain Despite Previous Decline
Although Health Catalyst shares have already gone through a significant decline in 2024, Evercore’s financial analysts believe that there is still potential for further downside risk. The primary cause for concern stems from the company’s financial performance, specifically challenges in maintaining steady growth in earnings and revenue. Evercore’s updated price target is based on a valuation of 8x the estimated 2025 EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization).
Short-term Factors Impacting Results
In the short term, Evercore has identified several critical factors likely to impact Health Catalyst’s financial performance. These include the transitional costs linked to the company’s decision to exit the unprofitable ambulatory TEMS (Technology, Equipment, and Medical Supplies) pilot program. Another influencing factor is the near-term margin drag associated with the onboarding of 10 new platform clients in the first quarter.
While both these strategic moves could support margin recovery later in the year, they are expected to affect the company’s first-quarter performance negatively. Despite the short-term challenges, these decisions are seen as necessary for the company’s long-term profitability and competitive edge in the healthcare technology market.
Long-term Challenges and Macro Risks
Looking at the long-term perspective, Evercore notes that despite hospital IT spending remaining positive, it has softened from previous highs. This trend could potentially impact Health Catalyst’s revenue growth, given the company’s focus on providing advanced analytic technology to healthcare organizations.
Simultaneously, macroeconomic risks are starting to emerge, including potential reductions in Medicaid coverage and an increase in expenses due to tariffs on medical supplies and pharmaceuticals. These additional pressures could further limit revenue growth while compressing profit margins, presenting significant challenges for the healthcare technology company.
Initiatives for Recovery
Despite these challenges, Evercore acknowledges that Health Catalyst has several strategies in place that could provide some financial relief. Initiatives like the migration to the Ignite platform and measures to improve TEMS profitability could benefit the company.
However, Evercore cautions that these potential gains may only partially offset the broader financial impact from the aforementioned pressures. The exact degree of offset will depend on the successful implementation of these initiatives and the volatility of the macroeconomic factors identified.
The downgrade by Evercore ISI serves as a cautionary note for investors and underscores the potential challenges facing Health Catalyst in both the near and long term. As the company navigates these uncertainties, investors will be keenly watching the execution of its strategic initiatives and its ability to manage macroeconomic pressures.